HealthdirectFree Australian health advice you can count on.

( ARTG ) NON-HODGKINS LYMPHOMA (NHL) RIXIMYO® (rituximab) is indicated for treatment of patients with: CD20 positive, previously untreated, Stage III/IV follicular, B-cell non-Hodgkins lymphoma, CD20 positive, relapsed or refractory low grade or follicular, B-cell non-Hodgkin's lymphoma, CD20 positive, diffuse large B-cell non-Hodgkins lymphoma, in combination with chemotherapy. CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) RIXIMYO® (rituximab) is indicated for the treatm‍​‍‍‍​‍‍‍‍‍‍‍‍​‍ent of patients with CD20 positive chronic lymphocytic leukaemia in combination with chemotherapy. RHEUMATOID ARTHRITIS (RA) RIXIMYO® (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumour necrosis factor (TNF) inhibitor therapy. Rituximab has been shown to reduce the rate of progression of joint damage as measured by x-ray when given in combination with methotrexate. GRANULOMATOSIS WITH POLYANGIITIS (WEGENERS) (GPA) AND MICROSCOPIC POLYANGIITIS(MPA) RIXIMYO® (rituximab) in combination with glucocorticoids is indicated for the induction of remission in patients with severely active Granulomatosis with polyangiitis (GPA, also known as Wegeners granulomatosis) and Microscopic polyangiitis (MPA). The efficacy and safety of retreatment with rituximab have not been established.